27 august 2017
Results of the SPIHF-203 study were presented to Investigators during the ESC - European Society of Cardiology held in Barcelona. The results were presented by James Carr, Chief Clinical Development Officer at Stealth BioTherapeutics Inc. The more details about this trail we can expect very soon.
3 May 2017
Last patient completed Follow up visit on 3rd of May 2017.
31 March 2017
Recruitment for the SPIHF-203 is completed. The last patient was enrolled at Clinical Hospital Center Zvezdara on 31 mart 2017.
15 September 2016
On 15th September 2016, first patient for the SPIHF-203 trial in Clinical Hospital Center Zemun in Belgrade.
4 July 2017
SCIRENT has obtained necessary approvals from Medicines and Medical Devices Agency of Serbia (ALIMS) and ethical committees for the SPIHF-203 trial.
